Register Login
Register to leave comments
  • News bot Jan. 7, 2026, 9:12 p.m.

    📋 Immuneering Corporation (IMRX) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 16:10:10

    Event Type: Clinical Trial Update

    Event Details:

    Immuneering Corporation (IMRX) Announces Clinical Trial Update Immuneering Corporation (IMRX) provided an update on its clinical development programs. Clinical Development Highlights: Clinical development progress update.

    🔬 Clinical Development Pipeline (Immuneering Corporation):

    Product Type Development Stage Therapeutic Area Source
    IMM-1-104 + pembrolizumab (Treatment Group E) DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    IMM-1-104 + dabrafenib (Treatment Group D) DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    IMM-1-104 + modified FOLFIRINOX (Treatment Group C) DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    IMM-1-104 Monotherapy (Treatment Group A) DRUG Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    IMM-6-415 DRUG Phase PHASE1 Advanced Solid Tumor (Phase 1) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Immuneering Corporation
    • CIK: 0001790340
    • Ticker Symbol: IMRX
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories